HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody.

Abstract
Chemotherapeutic drugs can enhance an immune response of the host against the tumor in addition to killing cancer cells by direct cytotoxicity. Therefore, the combination of chemotherapy and immunotherapy is a promising approach for eliminating tumors, particularly in advanced stages. A strategic medication is to use a bispecific antibody format that is capable of recruiting polyclonal T cells around antibody-target-expressing tumor cells. Recently, we have constructed a bispecific antibody, anti-CD3×anti-CD19, in a diabody configuration. In this study, we measured B7 family members B7.1 (CD80) and B7.2 (CD86) expressed on a CD19(+) human leukemia cell line, Nalm-6, stimulated by cytosine arabinoside (Ara-C). We found that a low concentration of Ara-C could upregulate CD80 expressed on CD19(+) Nalm-6 cells. The cytotoxicity of T lymphocytes against Nalm-6 cells in vitro and in vivo mediated by the anti-CD3×anti-CD19 diabody with or without a low dose of Ara-C was compared. The combination of the anti-CD3×anti-CD19 diabody and Ara-C showed the greatest effectiveness in enhancing the cytotoxicity of T cells against the tumor cells in vitro and in vivo. Activated T cells expressed higher levels of CD25 and CD69 and released more interleukin 2. Both perforin/granzyme B system and Fas/FasL pathway were involved in the diabody-induced T-cell cytotoxicity. Moreover, the activated T cells could upregulate ICAM-3 expression on Nalm-6 cells, and inhibition of LFA-1-ICAM-3 interaction impaired cytotoxicity of T cells. It was noted that Ara-C could upregulate CD80 expressed on two of five specimens of acute B lymphoblastic leukemia patient-derived cells. Cytotoxicity of T cells against these two patient-derived cells was enhanced in the presence of the anti-CD3×anti-CD19 diabody. These findings indicate that treatment strategy using both cytotoxic lymphocyte-based immunotherapy and chemotherapy may have synergistic effects.
AuthorsWei Li, DongMei Fan, Ming Yang, Yan Yan, RuiZan Shi, JunPing Cheng, ZhenZhen Li, MengNan Zhang, JianXiang Wang, Dongsheng Xiong
JournalHuman gene therapy (Hum Gene Ther) Vol. 24 Issue 8 Pg. 751-60 (Aug 2013) ISSN: 1557-7422 [Electronic] United States
PMID23879717 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bispecific
  • B7-1 Antigen
  • B7-2 Antigen
  • Cytarabine
Topics
  • Animals
  • Antibodies, Bispecific (metabolism)
  • B7-1 Antigen (drug effects, metabolism)
  • B7-2 Antigen (drug effects, metabolism)
  • Cell Line, Tumor
  • Cytarabine (pharmacology)
  • Cytotoxicity, Immunologic
  • Female
  • Humans
  • Leukemia (drug therapy, immunology)
  • Lymphocyte Activation (drug effects)
  • Mice
  • Mice, Nude
  • Mice, SCID
  • T-Lymphocytes (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: